BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: Phosphodiesterase-4 inhibitor
Date Journal Article title
2020 Mar Am J Clin Dermatol Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to lt; 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
2020 Mar Respir Res Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
2020 Mar Pharmacol Res TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
2020 Mar Nanomedicine (Lond) Suppression of neutrophilic inflammation can be modulated by the droplet size of anti-inflammatory nanoemulsions.
2020 Mar J Cutan Med Surg Off-Label Therapeutic Potential of Crisaborole.
2020 Hautarzt [Management of plaque psoriasis in adults].
2020 Feb Clin Gastroenterol Hepatol Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
2020 Exp Ther Med Transcriptomic analysis reveals moderate modulation of macrophage migration inhibitory factor erfamily genes in alcohol use disorders.
2020 Feb Expert Opin Pharmacother Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
2019 J Clin Aesthet Dermatol New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis.
2020 Int J Chron Obstruct Pulm... Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
2019 Front Cell Infect Microbiol Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.
2020 Medicine (Baltimore) Apremilast for the treatment of hidradenitis purativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
2019 Dec Med Lett Drugs Ther Drugs for psoriatic arthritis.
2020 J Cutan Med Surg Recalcitrant Seborrheic Dermatitis Successfully Treated With Apremilast.
2020 Jan J Drugs Dermatol Topical Agents for the Treatment of Atopic Dermatitis
2020 Jan Dermatol Ther Refractory palmoplantar pustulosis succesfully treated with apremilast.
2020 Mar Am J Physiol Renal Physiol Inhibition of PDE4PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury.
2020 Drugs Apremilast: A Review in Oral Ulcers of Behçet's Disease.
2020 Jan Sci Rep Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.
2020 Jan Clin Gastroenterol Hepatol Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.
2020 Feb Int J Pharm Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals.
2019 Front Pharmacol CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice.
2020 Feb Int J Pharm Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
2020 Mod Rheumatol Positioning of apremilast in treatment of Behçet's disease.
2019 Int J Trichology Apremilast in Refractory Alopecia Areata.
2019 Nov N Engl J Med Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
2020 Exp Parasitol The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.
2019 Dec Life Sci Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
2020 Cell Mol Neurobiol Inhibition of PDE4 Attenuates TNF-α-Triggered Cell Death Through Suppressing NF-κB and JNK Activation in HT-22 Neuronal Cells.
2020 J Dermatol Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
2012 LiverTox: Clinical and Re... Roflumilast
2012 LiverTox: Clinical and Re... Apremilast
2020 Redox Biol Inhibition of PDE4 protects neurons against oxygen-glucose deprivation-induced endoplasmic reticulum stress through activation of the Nrf-2HO-1 pathway.
2019 Aug Eur J Dermatol Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata.
2020 Ann Allergy Asthma Immunol New treatments for atopic dermatitis targeting beyond IL-4IL-13 cytokines.
2019 Pharmacol Res Biological and synthetic target DMARDs in psoriatic arthritis.
2019 J Aerosol Med Pulm Drug D... Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.
2019 Drug Discov Today Soft drugs for dermatological applications: recent trends.
2019 Expert Opin Investig Drugs Ensifentrine (RPL554): an investigational PDE34 inhibitor for the treatment of COPD.
2019 PLoS One Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder.
2019 J Allergy Clin Immunol Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
2020 J Am Acad Dermatol Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
2019 Aug Respir Res Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
2019 Jul Cell Death Dis Shifting the balance of autophagy and proteasome activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor homeostasis.
2019 Immunol Med Novel topical and systemic therapies in atopic dermatitis.
2019 Brain Behav Fear renewal activates cyclic adenosine monophosphate signaling in the dentate gyrus.
2019 Can J Physiol Pharmacol The contribution of phosphodiesterases to cardiac dysfunction in rats with metabolic syndrome induced by a high-carbohydrate diet.
2020 J Am Acad Dermatol Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
2019 Am J Clin Dermatol Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
2019 Jun Br J Dermatol Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
2019 Diabetes Metab Syndr Obes Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweightobesity involve age-associated fat mass loss - results of an exploratory study.
2019 Dec Rheumatology (Oxford) Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
2019 Therap Adv Gastroenterol New biologics and small molecules in inflammatory bowel disease: an update.
2019 Biologics Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau.
2019 J Dermatol Drug survival of apremilast in a real-world setting.
2018 Best Pract Res Clin Rheum... Emerging treatment options for spondyloarthritis.
2019 Environ Toxicol Pivotal role of cAMP-PKA-CREB signaling pathway in manganese-induced neurotoxicity in PC12 cells.
2019 Indian J Dermatol Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic.
2019 J Eur Acad Dermatol Venereol Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
2019 J Clin Aesthet Dermatol Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.
2019 Jun J Med Chem Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
2019 Hepatology Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.
2019 J Comp Eff Res Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
2019 CPT Pharmacometrics Syst ... Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase-4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation.
2019 Mol Pharmacol Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
2019 Jul Neuropharmacology The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition.
2019 Dermatol Ther Nails as immune-privileged sites: A case of disabling Acrodermatitis continua of Hallopeau successfully treated with Apremilast.
2020 Br J Dermatol Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
2019 J Dermatol Sci Cytochemokine profile of in vitro scratched keratinocyte model: Implications of significant upregulation of CCL20, CXCL8 and IL36G in Koebner phenomenon.
2019 J Surg Res Phosphodiesterase-4 Inhibitor Roflumilast Attenuates Pulmonary Air Emboli-Induced Lung Injury.
2019 Expert Opin Pharmacother Evaluating crisaborole as a treatment option for atopic dermatitis.
2019 Exp Ther Med Phosphodiesterase 4 inhibitor plus metformin is erior to metformin alone for the treatment of polycystic ovary syndrome: A rat model study.
2019 Skin Therapy Lett Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
2019 J Dermatol Favorable response to apremilast in a patient with refractory psoriasis verrucosa.